Author

R. Schiff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:proteomics· 2

Frequent Co-Authors

X. Fu· 2 shared A. B. Saltzman· 1 shared A. Feiglin· 1 shared A. Feit· 1 shared A. Font-Tello· 1 shared A. Gao· 1 shared A. Malovannaya· 1 shared A. Nardone· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

X. Fu

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

A. Nardone, X. Qui, A. Feiglin, X. Fu, S. Spisak, A. Feit, G. Cohen Feit, Y. Xie, A. Font-Tello, C. Guarducci, F. Hermida Prado, S. Syamala, K. Lim, M. Pun, M. Cornwell, , R. Jeselsohn

This study identifies a unique chromatin state in invasive lobular breast cancer (ILC) driven by FOXA1-ER axis, leading to tamoxifen resistance and poor outcomes.

bioRxiv · Mar 29, 2022Cancer Biology

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

L. Li, L. Lin, J. Veeraraghavan, Y. Hu, X. Wang, S. Lee, Y. Tan, R. Schiff, x. wang

This study investigates the role of ESR1-CCDC170 gene fusions in breast cancer endocrine resistance, showing they reduce endocrine sensitivity and can be targeted with HER2/SRC inhibitors.

bioRxiv · Jun 26, 2020Cancer Biology

Microscaled Proteogenomic Methods for Precision Oncology

S. Satpathy, E. J. Jaehnig, K. Krug, B.-J. Kim, A. B. Saltzman, D. Chan, K. R. Holloway, M. Anurag, C. Huang, P. Singh, A. Gao, N. Namai, Y. Dou, B. Wen, S. Vasaikar, , M. J. Ellis

This study develops microscaled proteogenomic methods for cancer analysis, showing treatment response and resistance mechanisms in ERBB2-positive breast cancers.

bioRxiv · Oct 9, 2019Cancer Biology

Coordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance

M. Bi, Z. Zhang, H. Wang, P. Xue, K. Hernandez, X. Fu, C. De angelis, Z. Gao, J. Ruan, V. Jin, Q. Wang, E. Marangoni, T. H.-M. Huang, L. Chen, C. K. Glass, , Z. Liu

This study identifies GATA3 and AP1-driven enhancer reprogramming as a mechanism promoting phenotypic plasticity and endocrine resistance in breast cancer.

bioRxiv · Sep 16, 2019Cancer Biology